Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset …

N Singh, C Wannstedt, L Keyes, T Gayowski… - …, 2005 - journals.lww.com
Background. The efficacy of valganciclovir used as preemptive therapy for cytomegalovirus
(CMV) disease in liver transplant recipients is not known. Methods. Between 1996 and 2004 …
被引用次数：131 相关文章

Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset …

N Singh, C Wannstedt, L Keyes… - …, 2005 - pubmed.ncbi.nlm.nih.gov
Background The efficacy of valganciclovir used as preemptive therapy for cytomegalovirus
(CMV) disease in liver transplant recipients is not known. Methods Between 1996 and 2004 …

Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset …

N Singh, C Wannstedt, L Keyes, T Gayowski… - …, 2005 - europepmc.org
Background The efficacy of valganciclovir used as preemptive therapy for cytomegalovirus
(CMV) disease in liver transplant recipients is not known. Methods Between 1996 and 2004 …

[引用][C] Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: Impact on viral load and late-onset …

N SINGH, C WANNSTEDT, L KEYES… - …, 2005 - pascal-francis.inist.fr
Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease
in liver transplant recipients: Impact on viral load and late-onset cytomegalovirus disease …

[引用][C] Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset …

N SINGH - Transplantation, 2005 - cir.nii.ac.jp
Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in
liver transplant recipients : impact on viral load and late-onset cytomegalovirus disease | CiNii …

Efficacy of Valganciclovir Administered as Preemptive Therapy for Cytomegalovirus Disease in Liver Transplant Recipients: Impact on Viral Load and Late-Onset …

N Singh, C Wannstedt, L Keyes, T Gayowski… - …, 2005 - journals.lww.com
Background. The efficacy of valganciclovir used as preemptive therapy for cytomegalovirus
(CMV) disease in liver transplant recipients is not known. Methods. Between 1996 and 2004 …

[引用][C] Efficacy of Valganciclovir Administered as Preemptive Therapy for Cytomegalovirus Disease in Liver Transplant Recipients: Impact on Viral Load and Late …

N Singh, C Wannstedt, L Keyes, T Gayowski… - Transplantation, 2005 - cir.nii.ac.jp
Efficacy of Valganciclovir Administered as Preemptive Therapy for Cytomegalovirus
Disease in Liver Transplant Recipients: Impact on Viral Load and Late-Onset …

[引用][C] Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: Impact on viral load and late-onset …

N SINGH, C WANNSTEDT, L KEYES… - …, 2005 - Lippincott Williams & Wilkins